NeoFipronis (Miaite) Instructions for Use
NeoFipronis (Pronidesivir) GS-441524 is a groundbreaking oral medication specifically designed for the treatment of Feline Infectious Peritonitis (FIP). Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis is the world's first officially registered FIP treatment drug. Its unique formulation offers cats a safe, non-invasive, and highly effective therapy option, delivering rapid absorption and minimal side effects.
FIP Symptoms and Treatment Overview
FIP is a serious viral disease affecting cats, characterized by symptoms such as anorexia, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological deficits, and uveitis. NeoFipronis targets these symptoms effectively by inhibiting the replication of the feline coronavirus responsible for FIP. Clinical studies have shown remarkable success in reducing illness severity and improving survival rates when used appropriately.
Active Ingredient and Mechanism
The active component of NeoFipronis is GS-441524, a nucleoside analog that inhibits viral RNA-dependent RNA polymerase. Extensive research and clinical trials demonstrate GS-441524's potent antiviral activity against FIPV. Its proven efficacy makes NeoFipronis a preferred choice for veterinarians and pet owners seeking reliable FIP treatment.
Dosage and Administration
The recommended dosage of NeoFipronis depends on the cat's weight. For general cases, administer 15 mg per kg of body weight once daily. This generally equates to half a tablet per kilogram. For cats with neurological or ocular forms of FIP, healthcare providers may increase the dose to 30 mg/kg according to medical guidance.
It is advisable to give NeoFipronis on an empty stomach—either one hour before meals or two hours after—to facilitate optimal absorption. Consistency is essential; the medication should be administered daily without interruption for a minimum of 12 weeks to ensure complete viral suppression. Interrupting treatment may reduce efficacy and increase the risk of relapse.
Monitoring and Precautions
During therapy, monitor the cat for changes in appetite, body temperature, and mental alertness. Regular blood tests should be conducted to evaluate liver and kidney functions and to detect any adverse effects early. Although NeoFipronis is an over-the-counter medication, it is strongly recommended to use under the supervision of a veterinarian familiar with FIP management. Proper dosing and adherence to treatment duration are critical for successful outcomes.
Safety and Warnings
NeoFipronis is strictly for feline use; it is not suitable for humans or other animals. Misuse can lead to unforeseen health issues. Only purchase NeoFipronis from authorized sources such as the official NeoFipronis website to ensure product authenticity and quality. While generally well-tolerated, some cats may experience minor side effects such as transient gastrointestinal disturbances or mild elevations in liver enzymes.
Conclusion
NeoFipronis (Pronidesivir) offers a swift, safe, and effective oral treatment for cats suffering from FIP. Its innovative formulation and proven antiviral activity position it as a key tool in feline infectious disease management. Owners and veterinarians should adhere to prescribed dosages and treatment protocols to maximize therapeutic success and improve the quality of life for affected cats.
Note: Always consult a veterinarian before initiating therapy with NeoFipronis. Proper diagnosis and monitoring are crucial to ensure safe and effective treatment outcomes.
